A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | Product name | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T77053 | Latozinemab | 98% |
Latozinemab
|
|
Latozinemab (AL001) is a potent and selective recombinant humanized monoclonal antibody against Sortilin.Latozinemab has a high affinity for Sortilin and interru... | ||||
T77054 | Lecanemab | 1260393-98-3 | 98% |
Lecanemab
|
Lecanemab (BAN-2401), an IgG1 monoclonal antibody targeting soluble aggregated amyloid beta (Aβ), demonstrates efficacy across Aβ oligomers, protofibrils, and in... | ||||
T77059 | Leronlimab | 674782-26-4 | 98% |
Leronlimab
|
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. leronlimumab has both anti-HIV and anti-tumor activity, inhibiting CCR-mediated HIV-1 vir... | ||||
T77075 | Spartalizumab | 1935694-88-4 | 98% |
Spartalizumab
|
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that selectively binds to PD-1 at low concentrations and shows high activity. Spartali... | ||||
T77092 | Nadecnemab | 98% |
Nadecnemab
|
|
Nadecnemab is an IGG4-κantibody targeting GFRA3, a receptor of the glial cell-derived neurotrophic factor family. Nadecnemab can be used for knee osteoarthritis ... | ||||
T77093 | Theralizumab | 906068-56-2 | 98% |
Theralizumab
|
Theralizumab (TGN1412) is an anti-CD28-targeting monoclonal antibody that directly stimulates T cells. Theralizumab has antitumor activity and is used for the tr... | ||||
T77099 | Nimacimab | 2098636-09-8 | 98% |
Nimacimab
|
Nimacimab is a recombinant humanized monoclonal antibody. It can improve diabetes and non-alcoholic steatohepatitis. | ||||
T77100 | Nirsevimab | 1989556-22-0 | 98% |
Nirsevimab
|
Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with a modified Fc region. Nirsevimab efficiently targets RSV-... | ||||
T77118 | Plozalizumab | 1610761-46-0 | 98% |
|
Plozalizumab (MLN-1202) is a humanized selective and potent anti-CCR2 antibody.Plozalizumab has antitumor activity.Plozalizumab is used in the study of malignant... | ||||
T77122 | Praluzatamab | 2145109-70-0 | 98% |
Praluzatamab
|
Praluzatamab is a monoclonal antibody targeting an activated white blood cell adhesion molecule (ALCAM/CD116). Praluzatamab is a naked antibody to Praluzatamab r... | ||||
T77124 | Osocimab | 2056878-75-0 | 98% |
Osocimab
|
Osocimab (BAY 1213790) is a potent anti-FXIa antibody with a Ki value of 2.4 nM and an EC50 value of 0.2 nM.Osocimab may reduce thrombosis through FXI inhibition... | ||||
T77125 | Otilimab | 1638332-55-4 | 98% |
Otilimab
|
Otilimab (GSK 3196165) is a humanized monoclonal antibody against granulocyt-macrophage colony-stimulating factor (GM-CSF). Otilimab has anti-inflammatory activi... | ||||
T77129 | Belantamab | 2061894-48-0 | 98% |
Belantamab
|
Belantamab (GSK2857914) is a humanized IgG1 monoclonal antibody against BCMA (TNFRSF17). Belantamab is a naked antibody to Belantamab mafodotin and can be used t... | ||||
T77132 | Clesrovimab | 2429913-18-6 | 98% |
|
Clesrovimab (MK1654) is an anti-respiratory syncytial virus protein F human monoclonal antibody for the prevention and treatment of respiratory syncytial virus i... | ||||
T77135 | Tafasitamab | 1422527-84-1 | 98% |
Tafasitamab
|
Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymp... | ||||
T77138 | Ragifilimab | 2207590-51-8 | 98% |
Ragifilimab
|
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting glucocorticoid-induced TNFR-associated protein (GITR). Ragifilimab can be used in the study... | ||||
T77149 | Cobolimab | 2022215-65-0 | 98% |
Cobolimab
|
Cobolimab (TSR-022) is a potent monoclonal antibody to TIM-3. Cobolimab induces internalization of TIM-3 with an IC50 value of 0.4464 nM. Cobolimab has antitumor... | ||||
T77170 | Siplizumab | 288392-69-8 | 98% |
Siplizumab
|
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody targeting CD2. Siplizumab selectively depletes effector memory T cells and promotes relative expans... | ||||
T77191 | Clivatuzumab | 1622075-09-5 | 98% |
Clivatuzumab
|
Clivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good the... | ||||
T35397 | Sacituzumab | 1796566-95-4 | 98% |
|
Sacituzumab is a humanized IgG1 monoclonal antibody, a naked antibody to Sacituzumab govitecan be used to synthesize antibody-active small-molecule couplings.Sac... |